8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Mar 30, 2026·SEC
Jasper Therapeutics, Inc.(JSPR)Earnings, Financials & Key Ratios
JSPR•NASDAQ
Price updated Jun 11, 2026
AboutJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Show more
- Revenue$0
- EBITDA-$79M-6.1%
- Net Income-$76M-6.4%
- EPS (Diluted)-3.95+19.2%
- ROE-230.31%-126.4%
- Debt/Equity0.30+912.1%
JSPR Key Insights
Jasper Therapeutics, Inc. (JSPR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 19.1% over 5 years
- ✗Weak Piotroski F-Score: 0/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when JSPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JSPR Price & Volume
Jasper Therapeutics, Inc. (JSPR) stock price & volume — 10-year historical chart
Loading chart...
JSPR Growth Metrics
Jasper Therapeutics, Inc. (JSPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM29.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.51%
Return on Capital
10 Years-94.54%
5 Years-110.05%
3 Years-133.14%
Last Year-184.59%
JSPR Peer Comparison
Jasper Therapeutics, Inc. (JSPR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 238.89M | 2.44 | -1.36 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 4.84B | 50.23 | -7.76 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 | |
 SGMO | 62.14M | 0.15 | -0.34 | -31.57% | -356.89% | -28.92% | ||
 IONS | 12.2B | 73.82 | -31.02 | 33.87% | -30.87% | -58.57% | 5.35 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 |
Compare JSPR vs Peers
Jasper Therapeutics, Inc. (JSPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JSPR Income Statement
Jasper Therapeutics, Inc. (JSPR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 1.06M | 21K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.06M▲ 0% | -21K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 4.71M | 20.68M | 36.83M | 51.2M | 68.86M | 76.24M | 79.46M | 73.01M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.09M | 4.8M | 11.41M | 16.57M | 17.08M | 20.42M | 18.94M | 20.25M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 3.62M | 15.88M | 25.42M | 34.63M | 51.78M | 55.82M | 60.52M | 52.76M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.71M▲ 0% | -20.68M▼ 339.1% | -36.83M▼ 78.1% | -51.2M▼ 39.0% | -68.86M▼ 34.5% | -76.24M▼ 10.7% | -80.52M▼ 5.6% | -73.03M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -339.13% | -78.08% | -38.99% | -34.5% | -10.71% | -5.61% | - |
EBITDA | 0 | 0 | -36.46M | -50.22M | -67.75M | -74.87M | -79.46M | -72.23M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | - | -37.76% | -34.91% | -10.5% | -6.14% | 11.48% |
D&A (Non-Cash Add-back) | 4.71M | 20.68M | 377K | 975K | 1.11M | 1.37M | 1.06M | 798K |
EBIT | -4.71M | -20.68M | -36.83M | -51.2M | -68.86M | -76.24M | -80.52M | -72.6M |
Net Interest Income | 533 | 0 | 0 | 701K | 5.2M | 5.06M | 1.74M | 1.28M |
Interest Income | 533 | 0 | 0 | 701K | 5.2M | 5.06M | 1.74M | 1.28M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -277K | -10.99M | 6.2M | 13.51M | 4.4M | 4.97M | 4.72M | 17.3M |
Pretax Income | -4.99M▲ 0% | -31.67M▼ 535.0% | -30.64M▲ 3.3% | -37.69M▼ 23.0% | -64.47M▼ 71.1% | -71.27M▼ 10.6% | -75.8M▼ 6.4% | -55.73M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.99M▲ 0% | -31.67M▼ 535.0% | -30.64M▲ 3.3% | -37.69M▼ 23.0% | -64.47M▼ 71.1% | -71.27M▼ 10.6% | -75.8M▼ 6.4% | -55.73M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -535.03% | 3.26% | -23% | -71.06% | -10.55% | -6.36% | 29.26% |
Net Income (Continuing) | -4.99M | -31.67M | -30.64M | -37.69M | -64.47M | -71.27M | -75.8M | -55.73M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | -183.08▲ 0% | -26.89▲ 85.3% | -10.33▲ 61.6% | -6.18▲ 40.2% | -4.89▲ 20.9% | -3.95▲ 19.2% | -3.63▲ 0% |
EPS Growth % | - | - | 85.31% | 61.58% | 40.17% | 20.87% | 19.22% | 32.51% |
EPS (Basic) | 0.00 | -183.08 | -26.89 | -10.33 | -6.18 | -4.89 | -3.95 | - |
Diluted Shares Outstanding | 176K | 172.98K | 1.14M | 3.65M | 10.44M | 14.58M | 15.33M | 15.33M |
Basic Shares Outstanding | 176K | 172K | 1.14M | 3.65M | 10.44M | 14.58M | 19.17M | 19.17M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
JSPR Balance Sheet
Jasper Therapeutics, Inc. (JSPR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 27.16M | 20.68M | 87.83M | 41.73M | 88.94M | 75.81M | 34.65M | 20.29M |
Cash & Short-Term Investments | 27.16M | 19.84M | 84.7M | 38.25M | 86.89M | 71.64M | 28.69M | 14.14M |
Cash Only | 27.16M | 19.84M | 84.7M | 38.25M | 86.89M | 71.64M | 28.69M | 14.14M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 600K | 0 | 0 | 250K | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 837K | 1.87M | 309K | 646K | 5.95M | 6.15M |
Total Non-Current Assets | 48K | 2.67M | 5.82M | 6.63M | 5.95M | 4.09M | 1.13M | 892K |
Property, Plant & Equipment | 0 | 2.03M | 4.83M | 5.45M | 4.19M | 2.85M | 604K | 398K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 417K | 417K | 0 | 417K |
Other Non-Current Assets | 48K | 643K | 990K | 1.18M | 1.34M | 820K | 530K | 494K |
Total Assets | 27.21M▲ 0% | 23.36M▼ 14.2% | 93.65M▲ 301.0% | 48.36M▼ 48.4% | 94.89M▲ 96.2% | 79.9M▼ 15.8% | 35.78M▼ 55.2% | 21.18M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -14.16% | 300.97% | -48.36% | 96.22% | -15.8% | -55.22% | -219.85% |
Total Current Liabilities | 1.99M | 4.01M | 8.02M | 7.07M | 12.37M | 15.24M | 13.2M | 9M |
Accounts Payable | 623K | 1.42M | 3.92M | 1.77M | 4.15M | 4.03M | 6.22M | 2.44M |
Days Payables Outstanding | - | - | - | - | - | - | 2.15K | 112.36K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.24M | 757K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1.33M | 785K | 194K | 5.49M | 3.7M | 5.75M | 5.8M |
Current Ratio | 13.63x | 5.16x | 10.95x | 5.91x | 7.19x | 4.98x | 2.62x | 2.26x |
Quick Ratio | 13.63x | 5.16x | 10.95x | 5.91x | 7.19x | 4.98x | 2.62x | 2.26x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 4.12M | 54.48M | 16.12M | 5.31M | 4.08M | 2.99M | 18.43M | 8.79M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 1.62M | 2.38M | 2.79M | 1.81M | 724K | 0 | 201K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.12M | 52.85M | 13.74M | 2.52M | 2.26M | 2.26M | 18.43M | 8.79M |
Total Liabilities | 6.11M | 58.49M | 24.14M | 12.37M | 16.45M | 18.23M | 31.63M | 17.78M |
Total Debt | 0 | 1.62M | 2.88M | 3.65M | 2.79M | 1.81M | 1.24M | 757K |
Net Debt | -27.16M | -18.21M | -81.82M | -34.6M | -84.1M | -69.82M | -27.46M | -13.39M |
Debt / Equity | - | - | 0.04x | 0.10x | 0.04x | 0.03x | 0.30x | 0.22x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.19x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 21.1M▲ 0% | -35.13M▼ 266.5% | 69.52M▲ 297.9% | 35.99M▼ 48.2% | 78.44M▲ 118.0% | 61.67M▼ 21.4% | 4.15M▼ 93.3% | 3.4M▲ 0% |
Equity Growth % | - | -266.48% | 297.89% | -48.23% | 117.96% | -21.37% | -93.27% | -347.96% |
Book Value per Share | 119.90 | -203.08 | 61.01 | 9.87 | 7.51 | 4.23 | 0.27 | 0.22 |
Total Shareholders' Equity | 21.1M | -35.13M | 69.52M | 35.99M | 78.44M | 61.67M | 4.15M | 3.4M |
Common Stock | 10K | 1K | 4K | 0 | 1K | 2K | 3K | 3K |
Retained Earnings | -5.14M | -36.81M | -67.45M | -105.14M | -169.6M | -240.87M | -316.67M | -317.84M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JSPR Cash Flow Statement
Jasper Therapeutics, Inc. (JSPR) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.97M | -18.27M | -33.68M | -45.86M | -52.07M | -62.6M | -77.16M | -68.87M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -827.73% | -84.37% | -36.17% | -13.54% | -20.23% | -23.26% | -20.43% |
Net Income | -4.99M | -31.67M | -30.64M | -37.69M | -64.47M | -71.27M | -75.8M | -55.73M |
Depreciation & Amortization | 0 | 0 | 377K | 1.31M | 1.11M | 1.37M | 1.06M | 798K |
Stock-Based Compensation | 6K | 1.21M | 1.05M | 0 | 5.21M | 6.62M | 6.71M | 4.9M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.62M | 10.9M | -6.09M | -8.83M | 976K | 502K | -4.21M | -13.43M |
Working Capital Changes | 1.39M | 1.3M | 1.62M | -649K | 5.1M | 173K | -4.92M | -5.4M |
Change in Receivables | 0 | 0 | 600K | -663K | 663K | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 358K | 2.94M | -2.15M | 2.38M | -122K | 2.19M | -549K |
Cash from Investing | 0 | 0 | -2.43M | -576K | -267K | -532K | 5K | 1K |
Capital Expenditures | 0 | 0 | -2.43M | -576K | -267K | -552K | -7K | -7K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 20K | 12K | 8K |
Cash from Financing | 29.13M | 11.29M | 100.97M | 55K | 100.97M | 47.88M | 34.21M | 34.21M |
Debt Issued (Net) | 1.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 11.23M | 10.75M | 55K | 101.48M | 47.2M | 34.21M | 6.11M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 27.63M | 53K | 90.22M | 0 | -508K | 689K | 0 | 28.1M |
Net Change in Cash | 27.16M▲ 0% | -6.98M▼ 125.7% | 64.86M▲ 1029.3% | -46.45M▼ 171.6% | 48.64M▲ 204.7% | -15.25M▼ 131.4% | -42.95M▼ 181.6% | -34.66M▲ 0% |
Free Cash Flow | -1.97M▲ 0% | -18.27M▼ 827.7% | -36.11M▼ 97.7% | -46.43M▼ 28.6% | -52.33M▼ 12.7% | -63.15M▼ 20.7% | -77.17M▼ 22.2% | -68.87M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -827.73% | -97.66% | -28.6% | -12.71% | -20.67% | -22.19% | 1.94% |
FCF per Share | -11.19 | -105.60 | -31.69 | -12.73 | -5.01 | -4.33 | -5.03 | -4.49 |
FCF Conversion (FCF/Net Income) | 0.39x | 0.58x | 1.10x | 1.22x | 0.81x | 0.88x | 1.02x | 1.24x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JSPR Key Ratios
Jasper Therapeutics, Inc. (JSPR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -178.18% | -71.44% | -112.67% | -101.73% | -230.31% | -523.04% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 258.46% |
| Debt / Equity | - | 0.04x | 0.10x | 0.04x | 0.03x | 0.30x | 0.22x |
| FCF Conversion | 0.58x | 1.10x | 1.22x | 0.81x | 0.88x | 1.02x | 1.24x |
Related:JSPR Dividend History·JSPR Revenue History·JSPR Price History·JSPR P/E History·JSPR Financial Ratios·JSPR Institutional Holders
JSPR SEC Filings & Documents
Jasper Therapeutics, Inc. (JSPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
JSPR Frequently Asked Questions
Jasper Therapeutics, Inc. (JSPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Jasper Therapeutics, Inc. (JSPR) grew revenue by 0.0% over the past year. Growth has been modest.
Jasper Therapeutics, Inc. (JSPR) reported a net loss of $55.7M for fiscal year 2025.
Dividend & Returns
Jasper Therapeutics, Inc. (JSPR) has a return on equity (ROE) of -230.3%. Negative ROE indicates the company is unprofitable.
Jasper Therapeutics, Inc. (JSPR) had negative free cash flow of $68.9M in fiscal year 2025, likely due to heavy capital investments.